Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Astrazeneca Pharma India Ltd (ASTRAZEN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506820 NSE: ASTRAZEN Pharmaceuticals & Drugs | Small Cap | Astrazeneca Pharma Share Price
₹8,210.30 36.40 (0.45%)
As on 05-Aug'26 12:39
Astrazeneca Pharma India Ltd (ASTRAZEN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506820 NSE: ASTRAZEN Pharmaceuticals & Drugs | Small Cap | Astrazeneca Pharma Share Price
₹8,210.30 36.40 (0.45%)
As on 05-Aug'26 12:39
Key Metrics
Valuation Multiples
Market Cap
₹20,435 Cr.
Current Price
₹8,210.3
52-Week Low / High
₹7,630 / 9,850
TTM EPS
₹75
TTM Sales
₹2,276 Cr.
Book Value per Share
₹346.5
P/E Ratio
108.97
In line with its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
23.59
Higher than its 5-year historical median
Price to Sales (P/S)
8.98
Lower than its 5-year historical median
EV/EBITDA
68.79
Higher than its 5-year historical median
Dividend Yield
0.44%
Profitability Efficiency
Return on Equity (ROE)
23.02%
Outperforms industry median
Return on Capital Employed (ROCE)
31.24%
Outperforms industry median
Return on Assets (ROA)
8.90%
Operating Profit Margin
11.5%
Net Profit Margin
8.24%
Gross Profit Margin
12.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
32.59%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
3.17%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
62.02%
Asset Quality
Promoter Holding
75.00%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹861 Cr.
Equity
₹5 Cr.
Face Value
₹2
All Time Low / High
₹9.00 / 10653.05
Check Before You Invest
Quality
Very GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Astrazeneca Pharma India Ltd a good quality company?
Astrazeneca Pharma India Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Astrazeneca Pharma India Ltd performance compare with that of its Peers?
Revenue growth of Astrazeneca Pharma India Ltd vs industry peers?
Astrazeneca Pharma India Ltd revenue CAGR is 22.84%, compared to the industry median CAGR of 5.55%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Astrazeneca Pharma India Ltd?
Promoters hold 75.00% of the Astrazeneca Pharma India Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Astrazeneca Pharma India Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 23.3% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.7% | 18.7% | 26.5% | 34.6% | 31.2% | 17.4% | 24.5% | 33.9% | 21.3% | 31.2% | - |
| Value Creation Index ⓘ | 0.3 | 0.3 | 0.9 | 1.6 | 1.3 | 0.3 | 0.8 | 1.5 | 0.6 | 1.8 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,276 |
| Sales YoY Gr. | - | 5% | 27.6% | 14.2% | -2.2% | -1% | 24.5% | 29.2% | 32.5% | 32.6% | - |
| Adj EPS ⓘ | 5.9 | 10.5 | 21.6 | 28.9 | 36.9 | 23.9 | 50.2 | 60.1 | 73.4 | 76.4 | 75 |
| YoY Gr. | - | 76.5% | 106.5% | 34.1% | 27.4% | -35.2% | 110.1% | 19.8% | 22.1% | 4.1% | - |
| BVPS (₹) ⓘ | 88.5 | 97.9 | 119.5 | 145.1 | 181.8 | 203.8 | 234.5 | 283.5 | 305.3 | 346.5 | 346.5 |
| Adj Net Profit ⓘ | 14.8 | 26.1 | 54 | 72.3 | 92.2 | 59.7 | 126 | 150 | 184 | 191 | 188 |
| Cash Flow from Ops. ⓘ | 38.1 | 8.8 | 55 | 87.4 | 105 | 101 | 58.3 | 27.9 | 65.4 | -15.1 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 17.2% | 22.8% | 31.4% | 32.6% | ||||
| Adj EPS ⓘ | 32.9% | 15.7% | 15% | 4.1% | ||||
| BVPSⓘ | 16.4% | 13.8% | 13.9% | 13.5% | ||||
| Share Price | 23.3% | 18.9% | 29.3% | -7.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 7.8 | 11.1 | 19.7 | 21.7 | 22.5 | 12.3 | 22.8 | 23.1 | 24.8 | 23.3 | 21.7 |
| Op. Profit Mgn % ⓘ | 6.9 | 8.2 | 9.8 | 14.6 | 16.7 | 10.7 | 16.5 | 14.3 | 14.8 | 11.5 | 11.5 |
| Net Profit Mgn % ⓘ | 2.7 | 4.6 | 7.4 | 8.7 | 11.3 | 7.4 | 12.5 | 11.6 | 10.7 | 8.4 | 8.2 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 185 | 216 | 176 | 167 | 193 | 200 | 185 | 179 | 206 | 243 | 126 |
| Cash Conv. Cycle ⓘ | 11 | 12 | -0 | -2 | -1 | 6 | 4 | 23 | 50 | 65 | 57 |
Valuation of Astrazeneca Pharma - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 544 | 571 | 728 | 832 | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 |
| Operating Expenses ⓘ + | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 2,014 |
| Operating Profit ⓘ | 37 | 46 | 71 | 121 | 135 | 86 | 165 | 184 | 254 | 262 |
| Operating Profit Margin (%) | 6.8% | 8.1% | 9.8% | 14.5% | 16.7% | 10.7% | 16.5% | 14.2% | 14.8% | 11.5% |
| Other Income ⓘ + | 14 | 12 | 16 | 13 | 13 | 15 | 26 | 35 | 41 | 28 |
| Interest ⓘ | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Depreciation ⓘ | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 29 |
| Profit Before Tax ⓘ | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 252 |
| Tax ⓘ | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 | 41 | 65 |
| Profit After Tax | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 188 |
| PAT Margin (%) | 3.7% | 4.5% | 7.5% | 8.7% | 11.5% | 7.7% | 9.9% | 12.5% | 6.7% | 8.2% |
| Adjusted EPS (₹) | 8.0 | 10.4 | 21.8 | 28.9 | 37.3 | 24.6 | 39.7 | 64.6 | 46.3 | 75.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 3.50% | 5.40% | 40.60% | 40.30% | 37.20% | 69.10% | 48% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 221 | 245 | 299 | 363 | 455 | 509 | 586 | 709 | 763 | 866 | |
| Debt + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 88 | 127 | 168 | 210 | 178 | 190 | 228 | 197 | 456 | 783 | |
| Others Liabilities ⓘ | 205 | 203 | 124 | 203 | 241 | 277 | 328 | 372 | 618 | 728 | |
| Total Liabilities ⓘ | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,277 | 1,838 | 2,377 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 87 | 75 | 75 | 72 | 81 | 74 | 69 | 67 | 64 | 117 | |
| CWIP ⓘ | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 | 0 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 58 | 113 | 118 | 165 | 160 | 140 | 190 | 228 | 549 | 1,027 | |
| Trade Receivables | 43 | 55 | 80 | 83 | 85 | 86 | 108 | 153 | 185 | 214 | |
| Cash Equivalents | 116 | 126 | 173 | 253 | 352 | 448 | 500 | 506 | 537 | 449 | |
| Others Assets ⓘ | 206 | 203 | 138 | 179 | 192 | 226 | 274 | 323 | 503 | 570 | |
| Total Assets ⓘ | 514 | 575 | 591 | 776 | 874 | 977 | 1,142 | 1,277 | 1,838 | 2,377 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Cash Flow From Investing Activity ⓘ + | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| Net Cash Flow ⓘ | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 | -88 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 10.63 | 11.12 | 20.03 | 21.83 | 22.83 | 12.78 | 18.13 | 24.95 | 15.73 | 23.02 |
| ROCE (%) | 18.74 | 18.65 | 26.53 | 34.61 | 31.24 | 17.36 | 24.49 | 33.94 | 21.29 | 31.24 |
| Asset Turnover Ratio | 1.16 | 1.05 | 1.25 | 1.22 | 0.99 | 0.87 | 0.95 | 1.08 | 1.11 | 1.08 |
| PAT to CFO Conversion(x) | 1.9 | 0.35 | 1.02 | 1.21 | 1.13 | 1.63 | 0.59 | 0.17 | 0.56 | -0.08 |
| Working Capital Days | ||||||||||
| Receivable Days | 42 | 31.20 | 33.50 | 35.60 | 37.60 | 38.60 | 35 | 36.50 | 35.80 | 31.90 |
| Inventory Days | 44.70 | 54.50 | 57.70 | 61.90 | 72.60 | 67.60 | 59.90 | 58.60 | 82.30 | 126 |
| Payable Days | 194.30 | 220 | 237.80 | 229.90 | 246.50 | 220.50 | 214.90 | 131.30 | 124.40 | 163.80 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Astrazeneca Pharma India Ltd FAQs
The current trading price of Astrazeneca Pharma on 05-Aug-2026 12:39 is ₹8,210.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Aug-2026 the market cap of Astrazeneca Pharma stood at ₹20,434.8 Cr
The latest P/E ratio of Astrazeneca Pharma as of 04-Aug-2026 is 109.0.
The latest P/B ratio of Astrazeneca Pharma as of 04-Aug-2026 is 23.59.
The 52-week high of Astrazeneca Pharma is ₹9,850 and the 52-week low is ₹7,630.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma is ₹2,276 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a good quality company.
The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Astrazeneca Pharma India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Astrazeneca Pharma India Ltd
AstraZeneca Pharma India (AZPIL), incorporated on July 11, 1979, is a global, science-led, patient-focused pharmaceutical company. The company is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom. The company is dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. The company’s focus areas in India include BioPharmaceuticals, Oncology, and Rare Diseases, which are pivotal to its Growth Through Innovation strategy.
The company operates with purpose and integrity, using science, innovation, and global reach to deliver life-changing medicines. It is committed to equitable access, healthier communities, and environmental responsibility across its value chain. By embedding sustainability at its core and following the science, the company strives to improve health outcomes and create lasting value for patients, society, and the planet.
Rated as one of the finest in South East Asia, AstraZeneca’s Indian manufacturing facility has a sophisticated production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged environment management system in place.
The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products. Guided by the values & processes of AstraZeneca, international guidelines & local regulatory framework the team collaborates with top-notch healthcare practitioners and medical institutes to bring AstraZeneca’s medicines as quickly, safely and efficiently as possible.
Business area of the company
AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products.
Core Therapy Areas
- Oncology
- BioPharmaceuticals
- Rare Disease
Milestones and achievements
- 1979: Formation of AstraIDL, promoted by Astra Pharmaceuticals AB Sweden and IDL Chemicals Hyderabad.
- 1982: Astra-IDL listed on the Bombay Stock Exchange (BSE) - 5.6 times oversubscription.
- 1982: Foundation stone of the Yelahanka site laid by the Prime Minister of Sweden.
- 1988: Started maternal health product division.
- 1989: Launched Restomycin, Bromenyl, Febrafen and Prostodin.
- 1996: Inauguration of R&D Centre in Bengaluru.
- 1998: Astra IDL touched its first Rs 100 crore mark with a revenue of Rs 102.47 crore.
- 1999: AstraZeneca formed by the global merger of Astra and Zeneca.
- 2001: AstraZeneca announced it had completed a transaction to buy a controlling stake in the joint venture company Astra-IDL and renamed it AstraZeneca Pharma India Ltd.
- 2001: Introduction of Seloken XL. Partnership with Bristol-Myers Squibb (BMS).
- 2003: Launch of Seloken XL.
- 2010: Launch of Young Health Programme (YHP) in India.
- 2011: AstraZeneca crosses Rs 500 crore turnover mark.
- 2012: Launch of Brilinta.
- 2014: Move of commercial operations and clinical operations to Manyata Tech Park, Bengaluru.
- 2014: Launch of new tablet production facility.
- 2014: Launch of Global Technology Chennai (GTC).
- 2015: Launch of Forxiga.
- 2016: AZ IT’s three-year IT Transformation Journey completed successfully in 2016.
- 2017: Launch of Tagrisso.
- 2017: Launch of GBS Global Commercial Operations India.
- 2018: Launch of the first Metabolic Centre of Excellence.
- 2019: 40th anniversary of AstraZeneca and launch of India- Sweden Healthcare Innovation Centre.
- 2021: AstraZeneca global’s COVID-19 vaccine saved more than six million lives worldwide. Around 3 billion vaccine doses supplied worldwide, with significant contributions to lowand middle-income countries.
- 2021: Establishing and expanding the CDI footprint in India: launched a clinical data and insights division in India to further strengthen its global presence, and for the management of data-related aspects of its clinical trials.
- 2022: Rebranded Global Technology Centre to Global Innovation Technology Centre (GITC).
- 2022: Established Clinical Regulatory Writing (CReW) to drive strategic medical writing excellence across R&D.
- 2023: Launched its India Bold Ambition aligning with its Growth Through Innovation Strategy.
- 2023: MoU with Government of Karnataka to deploy Artificial Intelligence (AI) based Lung Cancer screening technology in 19 district hospitals.
- 2023: Signed MoU with Roche Diagnostics India to improve diagnostics for breast cancer patients.
- 2023: Launched the global AZ Forest initiative in India in the state of Meghalaya.
- 2023: Expanded portfolio with Rare Disease Business Unit (BU) with the launch of Selumetinib.
- 2023: Expanded its R&D division in Bengaluru.
- 2024: MoU with Government of Goa to accelerate the detection of lung cancer in the state.
- 2024: AstraZeneca celebrates 45 years in India. Continued focus on accelerating the delivery of life-changing medicines and operating sustainably.
- 2024: AstraZeneca celebrates 10 years of GITC, India.
- 2024: AstraZeneca Pharma India and Mankind Pharma entered into an agreement for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India.
- 2025: AstraZeneca Pharma India (AstraZeneca) entered into distribution services agreement with Sun Pharmaceutical Industries (Sun Pharma) for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India.
- 2026: AstraZeneca Pharma India received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication.
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
